Top Page
Tryptamine Therapeutics
(Sydney:ENP)
Tryptamine Therapeutics (ENP) vs. iShares MSCI Australia ETF (EWA)
Tryptamine Therapeutics Business Overview & Revenue Model
Tryptamine Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 618.57K | 99.73K | 0.00 |
| Gross Profit | -54.34K | -54.34K | -6.77K | 618.57K | 99.73K | -1.01M |
| EBITDA | -6.85M | -5.27M | -6.70M | -5.10M | -8.27M | -11.66M |
| Net Income | -5.33M | -5.33M | -6.14M | -7.13M | -10.08M | -8.47M |
Balance Sheet | ||||||
| Total Assets | 6.66M | 6.66M | 7.45M | 5.88M | 13.61M | 21.46M |
| Cash, Cash Equivalents and Short-Term Investments | 3.03M | 3.03M | 5.37M | 1.64M | 4.85M | 12.72M |
| Total Debt | 0.00 | 0.00 | 0.00 | 1.53M | 3.74M | 1.36M |
| Total Liabilities | 699.17K | 699.17K | 1.83M | 1.75M | 4.81M | 2.59M |
| Stockholders Equity | 5.96M | 5.96M | 5.62M | 4.13M | 8.81M | 18.87M |
Cash Flow | ||||||
| Free Cash Flow | -7.90M | -7.90M | -6.00M | -4.03M | -9.72M | -9.51M |
| Operating Cash Flow | -7.77M | -7.77M | -6.00M | -4.03M | -8.59M | -7.89M |
| Investing Cash Flow | -133.40K | -133.40K | 1.68M | -9.08K | -1.24M | -1.80M |
| Financing Cash Flow | 5.60M | 5.60M | 9.27M | 2.39M | 1.95M | 20.61M |
Tryptamine Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Tryptamine Therapeutics Corporate Events
Tryptamine Therapeutics, operating through Entropy Neurodynamics Limited, is a psychedelic-focused biotechnology company developing novel neurotherapeutics for mental health indications. Director Jason Carroll strengthened his alignment with shareholders by purchasing 1 million ordinary shares on market for A$30,000, lifting his direct holding to 53.3 million shares while retaining his extensive suite of performance and incentive options, signaling confidence in the company’s trajectory amid its continuing capital structure commitments.
The most recent analyst rating on (AU:ENP) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Tryptamine Therapeutics stock, see the AU:ENP Stock Forecast page.
Entropy Neurodynamics reported a pivotal quarter marked by the successful enrolment and full dosing of the first patient in its world-first clinical trial of TRP-8803, an IV psilocin therapy for Binge Eating Disorder, conducted with Swinburne University. The patient completed two monitored infusions that demonstrated controlled, repeatable psychedelic exposure and favourable tolerability, with three of the planned 12 patients now enrolled and early data from the initial participant expected in the coming weeks. Financially, the company strengthened its balance sheet through a A$6.1 million placement and receipt of an A$847,186 R&D tax incentive, with further non-dilutive funding anticipated, providing capital to accelerate TRP-8803 clinical, manufacturing and regulatory programs. Together with a corporate rebrand to Entropy Neurodynamics and plans to launch a larger multi-indication trial this quarter, these developments underscore the company’s ambition to position TRP-8803 as a differentiated neuropsychiatric platform and reinforce its execution capabilities in the emerging psychedelic medicine sector.
The most recent analyst rating on (AU:ENP) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Tryptamine Therapeutics stock, see the AU:ENP Stock Forecast page.
Entropy Neurodynamics reported that the first Binge Eating Disorder patient treated with its IV psilocin candidate TRP-8803 in combination with psychotherapy has completed a four-week follow-up, showing clinically meaningful improvements across binge severity, mood, anxiety, body image satisfaction and overall wellbeing. Clinicians and management say the early, multi-domain benefits exceed expectations and support TRP-8803’s potential to offer a more controlled and scalable psychedelic-assisted therapy than oral psilocybin, with upcoming dosing of additional patients and higher-dose cohorts in early 2026 expected to guide further trial design, regulatory engagement and expansion into broader eating disorder and neuropsychiatric indications.
The most recent analyst rating on (AU:ENP) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on Tryptamine Therapeutics stock, see the AU:ENP Stock Forecast page.
Entropy Neurodynamics Limited has reported a change in the holdings of director Herwig Janssen, reflecting additional equity-based compensation in the form of fully paid ordinary shares. The company disclosed that Janssen received 1,931,012 new ordinary shares, valued at $64,109.59, issued in lieu of cash director fees for services provided between 12 May 2025 and 31 December 2025, following prior shareholder approval at the November 2025 AGM, underscoring the firm’s continued use of equity remuneration to conserve cash and further align board incentives with shareholder interests.
The most recent analyst rating on (AU:ENP) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Tryptamine Therapeutics stock, see the AU:ENP Stock Forecast page.
Entropy Neurodynamics has issued 1,931,012 fully paid ordinary shares to directors in lieu of cash fees, following shareholder approval at its November 2025 annual general meeting, and has lodged a corresponding Appendix 2A with the ASX. The company confirmed that the share issue was conducted without a prospectus under the Corporations Act’s secondary trading provisions, that it remains compliant with its financial reporting and continuous disclosure obligations, and that there is no excluded information, signaling routine governance and compensation management rather than a change in operating outlook.
The most recent analyst rating on (AU:ENP) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Tryptamine Therapeutics stock, see the AU:ENP Stock Forecast page.
Entropy Neurodynamics Limited has applied to the ASX for quotation of 1,931,012 new fully paid ordinary shares, issued on 16 January 2026 as non‑cash remuneration to directors in lieu of fees, pursuant to shareholder approval granted at the company’s November 2025 annual general meeting. The move modestly increases the company’s share count while conserving cash, signalling a continued emphasis on aligning director incentives with shareholders and preserving balance-sheet flexibility in a capital‑constrained environment.
The most recent analyst rating on (AU:ENP) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Tryptamine Therapeutics stock, see the AU:ENP Stock Forecast page.
Entropy Neurodynamics has reported that a Phase 2a trial conducted at the University of Florida showed its oral psilocybin candidate TRP-8802 produced rapid, sustained reductions in binge-eating behaviour among all evaluable Binge Eating Disorder patients, alongside improvements in anxiety, depression, psychological inflexibility and waist circumference, with an 80% reduction in binge episodes maintained through 14 weeks and severe BED eliminated by Week 6. The peer-reviewed publication of these results in the Journal of Eating Disorders is being positioned by the company as a key validation of its therapeutic approach and as strong support for the ongoing development of its lead asset, TRP-8803, an IV-infused psilocin formulation now being trialled in BED patients, which could enhance the company’s standing in the emerging psychedelic therapeutics field if replicated in larger studies.
The most recent analyst rating on (AU:ENP) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Tryptamine Therapeutics stock, see the AU:ENP Stock Forecast page.
Entropy Neurodynamics has disclosed a change in director Chris Ntoumenopoulos’ interests, with the allotment of 10 million director options exercisable at A$0.05 and expiring on 19 December 2030. The options, issued at no consideration and approved by shareholders at the company’s 13 November 2025 meeting, increase Ntoumenopoulos’ indirect holdings and further align his remuneration with long‑term shareholder value, underscoring the company’s continued reliance on equity-based incentives to retain and incentivise key leadership as it advances its therapeutic pipeline.
Entropy Neurodynamics Limited has notified the market of the issue of 2 million unquoted options, each exercisable at A$0.08 and expiring on 19 December 2027. The options, which form part of a previously announced transaction and will not be quoted on the ASX, modestly expand the company’s pool of unquoted equity and may provide additional incentive or funding flexibility for the business without immediately diluting existing shareholders in the traded ordinary shares.
Entropy Neurodynamics has notified the ASX that it will issue 50 million unquoted options exercisable at $0.05 and expiring on 19 December 2030 under an employee incentive scheme. The move increases the company’s pool of equity-based remuneration and may help align staff incentives with long-term shareholder value, while modestly diluting existing holders if the options are ultimately exercised.
Entropy Neurodynamics has received an $847,186 cash refund under Australia’s R&D Tax Incentive for its FY24 eligible research and development activities, reflecting a 48.5% tax offset on qualifying expenditure. The funds will be directed to its ongoing clinical trial of TRP-8803 for binge eating disorder with Swinburne University and to the broader clinical trial program, bolstering non-dilutive funding for the company’s pipeline of psilocin-based neuropsychiatric therapies and supporting its efforts to advance TRP-8803 from promising Phase 2a data toward more commercially viable, controlled psychedelic treatments.
Entropy Neurodynamics Limited has successfully completed the first patient dosing in its clinical trial for treating Binge Eating Disorder using TRP-8803, an IV-infused psilocin. This trial aims to provide controlled psychedelic experiences, which are crucial for the company’s strategy in delivering consistent psychedelic psychotherapy. The completion of this milestone, including DSMB safety clearance, sets the stage for further patient dosing and the potential for meaningful data that could support broader applications of TRP-8803 in treating eating disorders and other neuropsychiatric conditions.